MannKind (MNKD) Signs A New GLP 1 Partnership, Is The Stock Cheap?

MannKind’s new GLP-1 partnership puts inhaled weight-loss drug in focus

MannKind (MNKD) is back in the spotlight after a worldwide licensing and collaboration deal with Rose Pharma to develop ROSE-010 Technosphere, an inhaled GLP-1 candidate for weight management.

For investors watching MannKind, the Rose Pharma collaboration lands after a difficult stretch. The share price is down 36.1% year to date, and the 1-year total shareholder return has declined a similar 36.2%, despite a modest 0.9% 1-day share price gain.

Compare MannKind’s GLP-1 inhaled approach with other under-the-radar healthcare opportunities screened for balance sheet strength and fundamentals through our curated list of solid balance sheet and fundamentals (23 results).

MannKind now has a fresh GLP-1 story, a growing inhaled franchise, and a share price that has fallen hard. Does that mix leave the stock looking mispriced or fairly valued today?

Most Popular Narrative: 53% Undervalued

Against MannKind’s last close at $3.58, the most followed narrative pegs fair value at $7.59 per share. This highlights the current pricing gap that investors are trying to make sense of.

Afrezza's continued double-digit prescription growth, international expansion efforts, upcoming pediatric indication launch, and a broadened salesforce footprint are described as factors that may support market penetration in the context of a rising global diabetes burden and an aging population.

See why 9 investors see MannKind as 53% undervalued.

Result: Fair Value of $7.59 (UNDERVALUED)

Still, MannKind remains heavily exposed to Afrezza and Tyvaso DPI royalties, and rising R&D plus commercial costs could keep pressure on profitability if adoption disappoints.

Find out about the key risks to this MannKind narrative.

Next Steps

If the mixed tone around MannKind’s GLP-1 potential and existing royalty dependence feels unresolved, move quickly, study the data for yourself, and weigh the 3 key rewards and 1 important warning sign.

Looking for more MannKind-sized opportunities?

Do not stop your research with MannKind. Put other potential ideas on your radar now, or risk missing companies that better match your goals and risk tolerance.

• Target resilience first and scan a 11 resilient stocks with low risk scores to uncover businesses where balance sheet stress looks less likely to surprise you.
• Hunt for value gaps by checking a 29 high quality undervalued stocks that highlights companies combining quality fundamentals with prices that sit below their estimated worth.
• Spot future leaders early through a 16 high quality undiscovered gems that surfaces under-followed stocks with cleaner accounts and room to attract fresh attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com